28 research outputs found
On the use of a spatial cue as prior information for stereo sound source separation based on spatially weighted non-negative tensor factorization
Maternal smoking during pregnancy and birth defects in children: a systematic review with meta-analysis
Effect of cow's milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes
Arterial and venous vessels are required for modulating developmental relocalization and laterality of the interrenal tissue in zebrafish
10.1002/dvdy.22335Developmental Dynamics23971995-2004DEDY
Cascade of Boolean detector combinations
Abstract This paper considers a scenario when we have multiple pre-trained detectors for detecting an event and a small dataset for training a combined detection system. We build the combined detector as a Boolean function of thresholded detector scores and implement it as a binary classification cascade. The cascade structure is computationally efficient by providing the possibility to early termination. For the proposed Boolean combination function, the computational load of classification is reduced whenever the function becomes determinate before all the component detectors have been utilized. We also propose an algorithm, which selects all the needed thresholds for the component detectors within the proposed Boolean combination. We present results on two audio-visual datasets, which prove the efficiency of the proposed combination framework. We achieve state-of-the-art accuracy with substantially reduced computation time in laughter detection task, and our algorithm finds better thresholds for the component detectors within the Boolean combination than the other algorithms found in the literature
Rosiglitazone for type 2 diabetes mellitus.
BACKGROUND: Diabetes has long been recognised as a strong, independent risk factor for cardiovascular disease, a problem which accounts for approximately 70% of all mortality in people with diabetes. Prospective studies show that compared to their non-diabetic counterparts, the relative risk of cardiovascular mortality for men with diabetes is two to three and for women with diabetes is three to four. The two biggest trials in type 2 diabetes, the United Kingdom Prospective Diabetes Study (UKPDS) and the University Group Diabetes Program (UGDP) study did not reveal a reduction of cardiovascular endpoints through improved metabolic control. Theoretical benefits of the peroxisome proliferator activated receptor gamma (PPAR-gamma) activator rosiglitazone on endothelial function and cardiovascular risk factors might result in fewer macrovascular disease events in people with type 2 diabetes mellitus. OBJECTIVES: To assess the effects of rosiglitazone in the treatment of type 2 diabetes. SEARCH STRATEGY: Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library. SELECTION CRITERIA: Studies were included if they were randomised controlled trials in adult people with type 2 diabetes mellitus and had a trial duration of at least 24 weeks. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. Pooling of studies by means of fixed-effects meta-analysis could be performed for adverse events only. MAIN RESULTS: Eighteen trials which randomised 3888 people to rosiglitazone treatment were identified. Longest duration of therapy was four years with a median of 26 weeks. Published studies of at least 24 weeks rosiglitazone treatment in people with type 2 diabetes mellitus did not provide evidence that patient-oriented outcomes like mortality, morbidity, adverse effects, costs and health-related quality of life are positively influenced by this compound. Metabolic control measured by glycosylated haemoglobin A1c (HbA1c) as a surrogate endpoint did not demonstrate clinically relevant differences to other oral antidiabetic drugs. Occurrence of oedema was significantly raised (OR 2.27, 95% confidence interval (CI) 1.83 to 2.81). The single large RCT (ADOPT - A Diabetes Outcomes Progression Trial) indicated increased cardiovascular risk. New data on raised fracture rates in women reveal extensive action of rosiglitazone in various body tissues. AUTHORS' CONCLUSIONS: New studies should focus on patient-oriented outcomes to clarify the benefit-risk ratio of rosiglitazone therapy. Safety data and adverse events of all investigations (published and unpublished) should be made available to the public